NCT02010775 - Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

January 20, 2014

Primary Completion Date

March 7, 2017

Study Completion Date

November 29, 2017

Conditions

Masseter Muscle Hypertrophy

Interventions

BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

DRUG

Normal saline

Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.

Trial Locations (14)

Central Sydney Dermatology, Sydney

Shape Clinic, Darlinghurst

Esteem Beauty & Day Spa, Main Beach

The Rose Medical & Aesthetic Centre, North Fremantle

National Taiwan University Hospital, Taipei

Taipei Chang Gung Memorial Hospital of CGMF, Taipei

Tri-Service General Hospital, Taipei

Kaohsiung Medical University Hospital, Kaohsiung City

Dr. Jean Carruthers Cosmetic Surgery, Inc., Vancouver

Dr. Shannon Humphrey Inc., Vancouver

Project Skin MD, Vancouver

Pacific Dermaesthetics, Vancouver

Bertucci MedSpa, Woodbridge

Arthur Swift Research Inc., Montreal